Wall Street has perceived the company to have an almost unbreachable defense against competition with its offerings of ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.sbqKNnJW.js ...

The Wall Street Journal editorial board tore into President Donald Trump for pardoning the rioters who attacked the Capitol ...

The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling ...

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...

It wants to crush (forget 'turn back") the clock on diversity and inclusion in America. Fighting bac requires looking back - and getting it right this time.

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. We sell different types of products ...

Johnson & Johnson (JNJ ... despite the company beating Wall Street expectations on revenue by $70 million and reporting results on earnings per share in line with estimates.